Kappa Bioscience
Heart Health

Heart Health

Vitamin K2 - a proven way to bypass arterial calcification

Please click here to activate the video. After activation, data will be transmitted to the respective provider and you agree to our privacy policy.

Heart – Applications

See what CEO Egil Greve from Kappa Bioscience has to say about K2.

Play video

By clicking "Continue", data will be transmitted to the respective provider and you agree to our privacy policy.

Atherosclerosis: a severe heart health risk factor

Cardiovascular disease (CVD) is caused by disorders of the heart and blood vessels. CVD includes coronary heart disease (heart attacks) and cerebrovascular disease (stroke). Both are usually acute events and are mainly caused by a blockage that prevents blood flow to the heart or brain. The most common reason for this is a build-up of fatty calcium- rich deposits on and in the inner walls of the blood vessels that supply the heart or brain, known as atherosclerosis.

Vitamin K2 MK-7: clinically proven heart health ingredient

Studies on the effect of vitamin K2 MK-7 on cardiovascular health demonstrate a significant reduction in arterial stiffness and slower progression of calcification. Vascular calcification reduces arterial elasticity and results in stiffening of the vessels. Calcification of the arteries is closely linked to increased risk of cardiovascular disease. We see in patients an inverse relationship between calcification of vessels and survival. One of the strongest inhibitors of vessel calcification is the vitamin K-dependent matrix Gla protein (MGP).

K2VITAL® activates MGP

In the presence of vitamin K2, MGP is activated by carboxylation to become cMGP, which interacts with calcium in the bloodstream and regulates calcification in the vessel walls. With low levels of vitamin K2 in the bloodstream, MGP is present in its inactive form, which is in a de-phosphorylated and undercarboxylated state (dp-ucMGP) and will not be able to interact with calcium. This may lead to a higher calcification in the vessel wall.

Arterial stiffness was reduced with a 3-year MK-7 supplementation.

In a double-blinded, randomized, placebocontrolled clinical trial, arterial stiffness was investigated in 244 healthy postmenopausal women over a period of 3 years, supplemented with either 180 μg of MK-7 or a placebo. Among the participants with an elevated arterial stiffness at baseline, the stiffness index was significantly improved compared to the placebo group (p<0.05). A beneficial effect of MGP activation was also seen among the participants taking MK-7 which experienced a 50% decrease in circulating dp-ucMGP compared to the placebo group (p<0.0001). Several other studies have de - mon strated heart health benefits of vitamin K2 MK-7 (Knapen et al., 2015).

Vitamin K2 plays an important role in regulating calcium balance, influencing both bone and heart health. Calcium is needed by the body for skeleton building, muscle contraction, nerve signaling and other metabolic processes. However, excess calcium can have detrimental effects on health as it can accumulate in blood vessels and other soft tissues. There are several known correlations between bone and cardiovascular diseases. For instance, osteoporosis is linked to calcium deposits in blood vessels, a predictor of future heart complications. There is also an association between low bone mineral content in postmenopausal women and heart disease mortality. K2VITAL® is an ideal solution to this paradox. Supplementation with K2VITAL® directs calcium to the right place, to the bones, preventing both osteoporosis and arterial calcification at the same time.

Studies showing the effect of vitamin K2 MK-7 on cardiovascular health

  • Commercial
  • Quality & Safety
  • Product development
  • Science Papers
  • Applications
  • Experience Cards

Scalable capacity for mass-market production demands: Kappa’s current production capacity already exceeds the total projected yearly global vitamin K2 demand through 2020.
Industry-leading pricing: Kappa continuously reinvests in R&D and manufacturing processes to drive ingredient price points to levels that support commercial adoption. In 2017, Kappa led the market with a 45% price reduction – marking a significant step on the path to mass-market commercialization of K2.

Purity: all-trans vitamin K2 MK-7 (USP).
Quality: GMP, HACCP, ISO 22000:2005 manufacturing and distribution standards.
Stability: Patent-pending microencapsulation technology ensures stability in challenging formulations.
Long shelf life in finished products: 36 months shelf life on all ingredients; supported by extensive stability data on ingredients and finished formulations.
Approvals: Novel Food (EU), TGA (AUS), sGRAS (USA), drug registration in India (2017). Application processes are initiated in countries including China, Thailand and others. Kosher and Halal certifications.

Kappa developed the K2 Formulation LookBook, including more than 120 ready-to-use product formulations and dosage forms targeted towards all K2 health applications and a wide range of consumer groups.

Kappa’s on-going ExperienceCard Program develops innovative vitamin K2 formulations in collaboration with industry leaders. Each ExperienceCard concept represents a novel product formulation that is specifically designed to solve an existing market problem or to address a health segment or consumer group in a new way. K2VITAL® vitamin K2 MK-7 provides the central ingredient in each of the products. Partners provided synergistic co-ingredients, innovative dosage or manufacturing technology, or other elements that make these forward-looking products possible.

Bone Health

More information

Heart Health

More information

Customer Download Portal

Sign up | Reset password

Sales and Marketing
Kappa Ingredients GmbH
Friesenweg 4 | Building 13 | 22763 Hamburg

Kappa Bioscience AS
Silurveien 2 | Building B | 0380 Oslo

+49 40 6094087 0
Sales team USA: +1 609 201 1459